Fund moves
4.8%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LNTH · NASDAQ · Health Care Supplies
Lantheus Holdings (LNTH) · oqro.io/stocks/LNTH · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$102.10+0.10 (+0.10%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
No open-market purchase by an insider of Lantheus Holdings was filed in the last 90 days. The latest on record was on Mar 5, 2021.
Since 2016, Lantheus Holdings insiders reported 8 open-market purchases and 384 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2021.
No open-market sale by an insider of Lantheus Holdings (LNTH) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 2 trades in Lantheus Holdings (LNTH) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Gilbert Ray Cisneros Jr. (CA31).
Lantheus Holdings's next results are expected on Feb 24, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+93.4% (+$49.31) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $52.79 on Nov 19, 2025 to $102.10 on Nov 19, 2026 (+93.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 2 Congress trades, and 23 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Supplies company.
Last 12 months
+93.4%
Market value
$6.68B
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.64M shares sold short (5.6% of shares outstanding), +0.2% vs the previous count, 3.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Lantheus Holdings: 1 fund cut or exited a position in the latest available 13F filings and 1 member of Congress disclosed sales. 2 of 3 tracked groups show selling activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Revenue
$390M
+1.5% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net cash
$112M
Debt $572M, cash $684M, at Sep 30, 2026
Net income, last 12 months
$270M
Operating profit covers interest 14.7x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue, fiscal 2025
$1.54B
+0.5% vs the year before
Net income, fiscal 2025
$234M
As reported in the annual filing
Shares outstanding
65.4M
As of Nov 2, 2026
In fiscal 2025 the company spent $300M buying back its own shares. Cash actually paid, from its cash-flow statement.
New federal contracts from the last 12 months add up to 0.91% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Lantheus Holdings reported 8 open-market purchases and 384 sales since 2016; purchases in 2021.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $396M23×23 trades |
| 2024 | — | $19.5M43×43 trades |
| 2023 | — | $25.7M47×47 trades |
| 2022 | — | $17.6M68×68 trades |
| 2021 | $141K8×8 trades | $3.19M28×28 trades |
| 2020 | — | $2.58M21×21 trades |
| 2019 | — | $10.3M57×57 trades |
| 2018 | — | $1.77M16×16 trades |
| 2017 | — | $296M72×72 trades |
| 2016 | — | $67.5M9×9 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 24, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Lantheus Holdings's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Lantheus Holdings's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Top officer leaving
“Compensatory Arrangements of Certain Officers On November 6, 2025, the Company announced that Brian Markison, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), notified the Board on November 2, 2025, that he will retire from the Company effective December 31, 2025 (the “Effective Date”).”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Recent moves
Pentwater Capital Management LP went above 5%, with 6% · Schedule 13G, 2026
JANUS HENDERSON GROUP Ltd. fell below 5% (4.2%) · Schedule 13G, 2026
Farallon Capital Management, L.L.C. fell below 5% (4.8%) · Schedule 13G, 2026
FMR LLC fell below 5% (0.2%) · Schedule 13G, 2026
Vanguard Portfolio Management fell below 5% (4.88%) · Schedule 13G, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 18, 2025, LNTH is up 90.8% and the index fund is up 8.5%: 82 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much LNTH moves
Beta 0.5 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Deals
Things to keep in mind
Records
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
−6.5% on the year before ($1.06B)
+3.9% on the year before ($318M)
−9.1% on the year before ($95.5M)
+56% on the year before ($38.2M)
$0 the year before
+1.6% on the year before ($24.2M)
$384K the year before
The company also reports Product revenue, net ($1.51B), Total radiopharmaceutical oncology ($989M), Total precision diagnostics ($493M), License and royalty revenues ($34M), which group lines above and are not added again.
−1.7% on the year before ($1.48B)
+68% on the year before ($49.2M)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 14,000 words.
We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 26, 2025. Read the filing
And 26 more headings in the filing.
Information with respect to certain legal proceedings is included in Note 17, “Commitments and Contingencies,” to the consolidated financial statements contained in Part II, Item 8. “Financial Statements and Supplementary Data,” of this Form 10-K and is incorporated herein by reference.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Fails to deliver: 13K shares (about $1.28M) were not delivered on time for settlement on Oct 8, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 57.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (26.4% on ATS, 30.8% with other brokers), above its 26-week average of 51.6%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (17.7%), INTELLIGENT CROSS LLC (13.0%), ONECHRONOS (8.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.